Recent events
Recent events tied to this brand in public sources.
Back to profile29 entries · Page 1 of 2
2026
Lilly raises 2026 revenue outlook
Eli Lilly and Company raised its 2026 revenue outlook to $91 billion-$92 billion from $85 billion-$87 billion. It also raised its non-GAAP performance-margin outlook and lowered its non-GAAP earnings-per-share forecast.
2026
Jitai Technology and Eli Lilly form an AI-LNP platform partnership
Jitai Technology and Eli Lilly entered a strategic collaboration in which Jitai will use its AiLNP platform to develop LNP delivery technology, while Lilly will contribute resources in drug discovery, development, and commercialization.
2026
Pennsylvania sues insulin makers and PBMs over alleged insulin price collusion
Pennsylvania sued Eli Lilly and Co., Novo Nordisk Inc., Sanofi-Aventis US LLC, and several PBMs, alleging that they colluded to raise insulin prices. The lawsuit seeks structural changes, restitution, and financial penalties.
2026
Caspian Therapeutics raises $50 million in financing led by BVF Partners
Caspian Therapeutics has raised $50 million in financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura and other investors. The proceeds are expected to fund IND-enabling work, an initial clinical proof-of-concept program and advancement of a second menin inhibitor candidate.
2025
Indiana sues Eli Lilly over alleged insulin price-fixing
Indiana filed a lawsuit in Lake County Superior Court on Dec. 31 alleging that Eli Lilly conspired with pharmacy benefit managers to artificially inflate insulin list prices through secret rebates, charging roughly $300 to $700 for some insulin products. Lilly said it has taken industry-leading steps to lower insulin costs, including capping out-of-pocket costs at $35 per month and cutting list prices by 70%.
2022
FDA approves Jardiance for adults with heart failure
The FDA approved Boehringer Ingelheim's drug Jardiance, co-developed with Eli Lilly, to mitigate the risk of cardiovascular death and hospitalization for heart failure in adults.
2022
Arkuda Therapeutics completes $64 million Series B financing
Arkuda Therapeutics announced completion of a $64 million Series B financing co-led by Cormorant Asset Management and Pivotal bioVenture Partners, with participation from other new and existing investors. The company said the funding would support advancement of its lead program and expansion of its pipeline.
2021
Mozart Therapeutics announces $55 million Series A financing
Mozart Therapeutics announced a $55 million Series A financing led by ARCH Venture Partners, with Sofinnova Partners and additional investors participating. The company said it would use the funds to advance its lead CD8 Treg Modulator into the clinic and progress additional programs.
2021
FDA approves expanded Verzenio adjuvant-treatment use
The FDA approved Eli Lilly's Verzenio, in combination with endocrine therapy, for adjuvant treatment of certain adults with high-risk, node-positive, HR-positive/HER2-negative early breast cancer.
2021
Healthcare Pharmaceuticals launches Cyramza in Bangladesh
Healthcare Pharmaceuticals launched Cyramza, an injectable anti-cancer medicine, in Bangladesh in association with Eli Lilly and Company.
2021
Lilly and Lycia sign collaboration and licensing agreement
Eli Lilly and Lycia Therapeutics signed a multi-year collaboration and licensing agreement to discover, develop and commercialize therapeutics targeting areas including immunology and pain. Lilly will lead preclinical and clinical development and receive an exclusive worldwide commercialization license for potential medicines developed under the agreement.
2021
Menarini completes acquisition of Cialis in China
A. Menarini Asia-Pacific Holdings, part of Menarini Group, announced that it had completed its acquisition of Eli Lilly's Cialis brand in China and would take over the brand's ownership, sales, marketing and distribution.
2021
Arecor announces formulation study collaboration with Lilly
Arecor announced that it had signed a formulation study partnership with Eli Lilly and Company. Arecor said the collaboration concerns the potential development of a new formulation for a Lilly product.
2021
Natco and Lilly sign Baricitinib licensing agreement
Natco Pharma announced that it signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company to manufacture and commercialize Baricitinib for COVID-19 in India.
2021
Cipla signs baricitinib licensing agreement with Eli Lilly
Cipla announced that it signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for the manufacture and commercialization of baricitinib for COVID-19 in India.
2021
Rigel and Lilly close global license agreement and collaboration
Rigel Pharmaceuticals announced the closing of its global exclusive license agreement and strategic collaboration with Eli Lilly and Company. The agreement is effective March 27, 2021; Rigel received the $125 million upfront payment, and the collaboration covers co-development and commercialization of R552 and Lilly-led clinical development of penetrating RIPK1 inhibitors for CNS diseases.
2021
Elsevier releases updated DDIRC 2.0 in PharmaPendium
Elsevier, together with pharmaceutical collaborators, further refined and extended its drug-drug interaction risk calculator in PharmaPendium. The DDIRC 2.0 release includes updated visualizations and filters, a more comprehensive dataset, and improved dossier submission support.
2021
Lilly appoints Anat Ashkenazi as CFO successor
Eli Lilly and Co. appointed Anat Ashkenazi to replace Josh Smiley as chief financial officer.
2021
Lilly CFO Josh Smiley leaves the company
Eli Lilly and Co. said CFO Josh Smiley was leaving the company after an investigation found inappropriate personal communications with a Lilly employee.
2021
Lilly announces licensing agreement for AK1780
Eli Lilly and Asahi Kasei Pharma announced a licensing agreement giving Lilly exclusive rights to AK1780. Lilly will be responsible for its global development and regulatory activities, and the transaction remains subject to customary closing conditions.